CN113115943A - Composition capable of improving senile dementia syndrome and preparation method thereof - Google Patents
Composition capable of improving senile dementia syndrome and preparation method thereof Download PDFInfo
- Publication number
- CN113115943A CN113115943A CN201911392024.5A CN201911392024A CN113115943A CN 113115943 A CN113115943 A CN 113115943A CN 201911392024 A CN201911392024 A CN 201911392024A CN 113115943 A CN113115943 A CN 113115943A
- Authority
- CN
- China
- Prior art keywords
- parts
- fucoxanthin
- senile dementia
- brown algae
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 24
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 20
- 241000199919 Phaeophyceae Species 0.000 claims abstract description 18
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims abstract description 17
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 16
- 241000195493 Cryptophyta Species 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229940072056 alginate Drugs 0.000 claims description 5
- -1 alginate oligosaccharide Chemical class 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 14
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 230000009189 diving Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000206751 Chrysophyceae Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a composition containing DHA algal oil, brown algae oligosaccharide and fucoxanthin and having the effect of improving senile dementia syndrome and a preparation method thereof. The composition provided by the invention is obviously better than the single use of DHA algal oil, brown algae oligosaccharide and fucoxanthin in the aspect of improving the senile dementia syndrome, and has a synergistic effect.
Description
Technical Field
The invention relates to functional food or health food, in particular to a composition containing DHA algal oil, brown algae oligosaccharide and fucoxanthin and having the effect of improving senile dementia syndrome and a preparation method thereof.
Background
Senile dementia, also called Alzheimer Disease (AD), is a degenerative disease of the central nervous system, with an insidious onset and a chronic progressive course, and is one of the most common types of senile dementia. It is mainly manifested as progressive memory disorder, cognitive dysfunction, personality change and language disorder, and has serious influence on social, occupational and life functions. With the increasing aging and aging of the global population and the increasing life span of the population, the number of patients with senile dementia is gradually increased, and the senile dementia becomes a serious social problem. According to statistical data at home and abroad, the incidence rate of the senile dementia is up to 5% -10%, and the incidence rate of senile dementia patients over 80 years old in China is about 20%, about 700 thousands of patients account for about one fourth of the total number of cases in the world; the number of people affected by the disease is several times that of the disease, and the dementia patients cannot be cared for by relatives, so that the whole family is affected by illness of one person. Therefore, the development of a composition or a health-care product capable of improving the senile dementia syndrome has very important practical significance.
Senile dementia is a progressive neurodegenerative disease, and the pathogenesis is not clear up to now. The current medical technology has no ideal treatment scheme for the middle and late stages of the senile dementia, so the method has important effects on preventing and improving the senile dementia syndrome in the early stage of the senile dementia.
DHA, docosahexaenoic acid, commonly known as NAOHUANGJIN, is a polyunsaturated fatty acid very important to human body, and belongs to an important member in Omega-3 unsaturated fatty acid family. DHA is a main element for the growth and maintenance of nervous system cells, is an important constituent fatty acid of the brain, has a content of up to 20% in the cerebral cortex of a human body, and has the effects of enhancing memory and thinking ability, improving intelligence, promoting brain development, preventing brain degeneration caused by aging, and the like. The DHA can be synthesized by algae through self fermentation, so with the development of modern science and technology, people breed algae in a large stainless steel fermentation tank to finally obtain DHA algae oil. Compared with DHA from fish oil, the DHA algae oil is pure natural, has no heavy metal residue, has no fishy smell, is more stable and safe, belongs to sustainable renewable resources, and has reliable source.
The brown algae oligosaccharide is a linear oligomer consisting of beta-D-polymannuronic acid (M) and alpha-L-polymannuronic acid (G), and comprises three types of products, namely polymannuronic acid (PM), polymannuronic acid (PG) and hybrid brown algae oligosaccharide (PMG). Has multiple biological functions of resisting tumor, resisting blood coagulation, reducing blood sugar and blood fat, promoting growth and the like, and is widely applied in the field of medical care.
Fucoxanthin is a carotenoid widely distributed in algae such as brown algae, diatom, chrysophyceae and chlorella. At present, a plurality of research results and clinical tests show that fucoxanthin has the functions of resisting tumor, inflammation and oxidation, reducing weight and protecting nerve cells, particularly has the aspect of accelerating metabolism, and has good safety.
Disclosure of Invention
The invention aims to provide a composition for improving senile dementia syndrome and application thereof.
The invention adopts the following technical scheme to achieve the purpose.
The composition for improving the senile dementia syndrome comprises the following components in parts by weight: 20-50 parts of DHA algal oil, 50-100 parts of brown algae oligosaccharide and 0.1-1 part of fucoxanthin.
Preferably, the composition for improving the senile dementia syndrome comprises the following components in parts by weight: 30-40 parts of DHA algal oil, 50-70 parts of brown algae oligosaccharide and 0.1-0.5 part of fucoxanthin.
Further preferably, the composition for improving the senile dementia syndrome comprises the following components in parts by weight: 35 parts of DHA algal oil, 65 parts of brown algae oligosaccharide and 0.3 part of fucoxanthin.
The molecular weight of the brown algae oligosaccharide is 2000-3500 Da; the alginate oligosaccharide with the molecular weight more or less than the molecular weight can obviously reduce the efficacy of the composition in improving the senile dementia syndrome. Also, alginate oligosaccharides prepared by an enzymatic hydrolysis method are preferable.
The fucoxanthin has a purity of about 20%, and other components are heteropigments.
The preparation method comprises the following steps: pulverizing brown algae oligosaccharide and fucoxanthin, sieving with 80 mesh sieve, adding DHA algae oil, mixing, adding binder 4% (binder is 95% ethanol, and content is 4% of total weight of other components), adding appropriate adjuvant, making into soft mass, granulating, drying, grading, and making into granule or other dosage forms.
The weight parts can be the weight units known in the medical field such as mu g, mg, g, kg, and the like, and can also be multiples thereof such as 1/10, 1/100, 10, 100, and the like.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
The DHA algae oil is extracted from marine microalgae, and is purchased from Tianjin Yibeijian biotechnology limited company.
The brown alginate oligosaccharide is a small molecular weight fragment obtained by cracking brown alginate polysaccharide (also called algin) through an oxidant or a degrading enzyme, and is purchased from Tianjin Yibeijian biotechnology limited.
The fucoxanthin is extracted from brown algae and is purchased from Tianjin Yibeijian biotechnology limited.
In the preparation process of the invention, the used means are all conventional technical means in the field unless otherwise specified.
1 animal experiment.
1.1 test subjects.
35 female ICR mice, provided by the institute of laboratory animals of military medical science and academy of sciences of the people's liberation army, China.
1.2 administration by groups
The 35 mice were randomly divided into 5 groups, i.e., a blank control group, a model group, a low dose group, a medium dose group, and a high dose group, each of which was 5. Gavage 0.3ml distilled water for the blank control group and the model group mice once a day; mice in the low dose group, the middle dose group and the high dose group are respectively gavaged with 0.3ml of 2 mg/ml, 5 mg/ml and 10 mg/ml compositions. Except for a blank control group, three-dimensionally injecting 50 um/l A beta (beta-amyloid) into the brain of each group of mice one day before administration, respectively injecting 1 ul Abeta model into ventricles on two sides, then, intragastrically filling the corresponding drugs into each group of mice according to requirements for 30 days, continuously intragastrically filling the mice for 29 days after administration, training each group of mice by using a diving platform instrument, and measuring the time (latency) required by finding and jumping to a safe platform after administration for 1 h on the 30 th day; performing water maze training 2 times a day on the 25 th to 29 th days of administration; after the platform-skipping latency is measured on day 30, the Morris water maze is adopted for behavioural detection, the time for finding the platform (escape latency) and the swimming path (total distance) are recorded by the method, and comparison between groups is carried out. The results of the experiments are shown in table 1 below.
TABLE 1 diving platform and Water maze test results
| Group of | Diving platform latency/s | Maze latency/s | Total path/cm of maze |
| Normal group | 4.7±0.7 | 40.1±1.4 | 423.4±77.2 |
| Model set | 22.9±1.5 | 89.4±1.7 | 933.4±88.3 |
| Low dose compositions | 7.2±0.7 | 57.3±1.3 | 597.2±80.1 |
| Medium dose composition | 6.7±0.4 | 54.4±1.5 | 561.9±82.4 |
| High dose compositions | 6.1±0.5 | 49.7±1.6 | 503.7±74.3 |
From the results in table 1 above, it can be seen that the inventive composition can significantly improve the memory of the model group mice and has a dose dependency. The composition has the effect of improving the senile dementia syndrome.
Claims (8)
1. A composition for improving climacteric syndrome, which comprises the following components: DHA algal oil, brown algae oligosaccharide and fucoxanthin.
2. The composition according to claim 1, characterized in that it comprises the following ingredients in parts by weight: 20-50 parts of DHA algal oil, 50-100 parts of brown algae oligosaccharide and 0.1-1 part of fucoxanthin.
3. The composition according to claim 1, characterized in that it comprises the following ingredients in parts by weight: 30-40 parts of DHA algal oil, 50-70 parts of brown algae oligosaccharide and 0.1-0.5 part of fucoxanthin.
4. The composition according to claim 1, wherein the composition for improving the senile dementia syndrome comprises the following components in parts by weight: 35 parts of DHA algal oil, 65 parts of brown algae oligosaccharide and 0.3 part of fucoxanthin.
5. The alginate oligosaccharide of any one of claims 1-4, which has a molecular weight of 2000-3500 Da.
6. The fucoxanthin purity of the brown algae oligosaccharide of any one of claims 1-4 is 15% -25%.
7. A process for preparing a composition according to any one of claims 1 to 4, comprising the steps of:
1) pulverizing brown algae oligosaccharide and fucoxanthin, sieving with 80 mesh sieve, adding DHA algae oil, and mixing;
2) adding 95% ethanol and appropriate adjuvants into the above mixture at a ratio of 4% to make into soft mass, granulating, drying, grading, and making into granule or other dosage forms.
8. Use of the composition of any one of claims 1 to 7 for the preparation of a health product for ameliorating senile dementia syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911392024.5A CN113115943A (en) | 2019-12-30 | 2019-12-30 | Composition capable of improving senile dementia syndrome and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911392024.5A CN113115943A (en) | 2019-12-30 | 2019-12-30 | Composition capable of improving senile dementia syndrome and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113115943A true CN113115943A (en) | 2021-07-16 |
Family
ID=76767755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911392024.5A Pending CN113115943A (en) | 2019-12-30 | 2019-12-30 | Composition capable of improving senile dementia syndrome and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113115943A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113975235A (en) * | 2021-10-11 | 2022-01-28 | 浙江海洋大学 | Fucoxanthin-delivering brown alginate oligosaccharide-mesoporous silica nanocomposite |
| CN117137941A (en) * | 2023-09-20 | 2023-12-01 | 威海海高园明睿智琳生物科技有限公司 | A radiation-proof seaweed extract composition |
| CN117982529A (en) * | 2024-03-08 | 2024-05-07 | 威海明睿智琳生物科技有限公司 | Compositions, methods and uses for neuroprotection and treatment of a variety of neurodegenerative diseases |
-
2019
- 2019-12-30 CN CN201911392024.5A patent/CN113115943A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113975235A (en) * | 2021-10-11 | 2022-01-28 | 浙江海洋大学 | Fucoxanthin-delivering brown alginate oligosaccharide-mesoporous silica nanocomposite |
| CN113975235B (en) * | 2021-10-11 | 2023-01-24 | 浙江海洋大学 | Fucoxanthin-delivering brown alginate oligosaccharide-mesoporous silica nanocomposite |
| CN117137941A (en) * | 2023-09-20 | 2023-12-01 | 威海海高园明睿智琳生物科技有限公司 | A radiation-proof seaweed extract composition |
| CN117982529A (en) * | 2024-03-08 | 2024-05-07 | 威海明睿智琳生物科技有限公司 | Compositions, methods and uses for neuroprotection and treatment of a variety of neurodegenerative diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113115943A (en) | Composition capable of improving senile dementia syndrome and preparation method thereof | |
| EP2124972B1 (en) | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems | |
| EA030161B1 (en) | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof | |
| EA034980B1 (en) | Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, methods of making and uses thereof | |
| JP6435333B2 (en) | Composition for prevention and treatment of cancer-related fatigue comprising processed ginseng powder or processed ginseng extract with increased ginsenoside component | |
| JP2022538212A (en) | Very long chain fatty acids for disease treatment and alleviation | |
| CN110638798B (en) | Use of alkylresorcinols in the preparation of a product for preventing or treating obesity-related diseases | |
| KR20150055876A (en) | Composition for reducing body-fat and weight | |
| JP2017149749A (en) | Pharmaceutical composition for preventing or treating sarcopenia, and health functional food composition for preventing or improving sarcopenia | |
| CN105998072A (en) | Pig brain extract, composition containing pig brain extract and application of composition | |
| CN107405329B (en) | Composition for improving circadian rhythm | |
| KR20220012381A (en) | A composition for inhibiting senescence comprising Akkermansia muciniphila or culture of the same | |
| Radzun et al. | Anti-inflammatory Effects of Astaxanthin Extracted from Microalgae Hematococcus pluvialis and Combinations with Palm Tocotrienol Rich-Fraction in RAW 264.7 Macrophages | |
| Vamanu et al. | Therapeutic potential of functional product based on wild edible mushrooms | |
| WO2018186492A1 (en) | Non-rem sleep promoter, non-rem sleep inducer, deep sleep promoter, deep sleep inducer, sleep improver, food composition for promoting non-rem sleep, food composition for inducing non-rem sleep, food composition for promoting deep sleep, food composition for inducing deep sleep, and food composition for improving sleep | |
| JP2017147960A (en) | Proliferation stimulant of intestinal blautia coccoides, anxiety-ameliorating agent, and therapeutic agent for inflammation of intestine | |
| CN106031722A (en) | Composition for treating diseases caused by body and nervous system disorder or inflammation, and applications thereof | |
| CN103932179A (en) | Health food for relieving stress and protecting liver and two-step fermentation preparation method of health food | |
| JP6499740B2 (en) | Food composition | |
| Murray | Pyrroloquinoline quinone (PQQ): The next essential nutrient and supplement superstar | |
| JP2019172614A (en) | Gene expression control agent, and muscular atrophy inhibitor, preventive or improver | |
| CN111329928B (en) | Composition containing camellia oil and application thereof | |
| Paidi et al. | Marine Natural Products in the Management of Diabetes Mellitus | |
| CN116035979B (en) | Relief repair composition, essence and preparation method thereof | |
| JP7536441B2 (en) | Pharmaceutical composition for preventing or treating sarcopenia and functional health food composition for preventing or improving sarcopenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210716 |
|
| WD01 | Invention patent application deemed withdrawn after publication |